News
-
-
-
PRESS RELEASE
Neovii Advances FDA Fast Track-Designated ATLG Program in Type 1 Diabetes with Pivotal Phase 2 study // Company appoints physician-scientist Salvatore Alesci as Chief Medical Officer
Neovii Pharmaceuticals AG advances ATLG Program in Type 1 Diabetes with pivotal Phase 2 study and appoints Salvatore Alesci as Chief Medical Officer -
-
-
PRESS RELEASE
EQS-Adhoc: YOC AG: Preliminary Figures for Q3/2026 – Adjustment of the Full-Year Guidance 2026
YOC AG revises full-year guidance for 2026 based on preliminary figures for Q3/2026, expecting lower EBITDA and revenue due to challenging market conditions in the digital advertising industry -
-
-
-